Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Bosch OJ, Nair HP, Ahern TH, Neumann ID, Young LJ (2009). The CRF system mediates increased passive stress-coping behavior following the loss of a bonded partner in a monogamous rodent. Neuropsychopharmacol, in press.
Keller MC, Neale MC, Kendler KS (2007). Association of different adverse life events with distinct patterns of depressive symptoms. Am J Psychiatry 164: 1521–1529.
Krebs HA (1975). The August Krogh principle: ‘For many problems there is an animal on which it can be most conveniently studied. J Exp Zoology 194: 221–226.
Law AJ, Pei Q, Walker M, Gordon-Andrews H, Weickert CS, Feldon J et al (2009). Early parental deprivation in the marmoset monkey produces long-term changes in hippocampal expression of genes involved in synaptic plasticity and implicated in mood disorder. Neuropsychopharmacol, in press.
Meltzer HY (1988). New insights into schizophrenia through atypical antipsychotic drugs. Neuropsychopharmacol 1: 193–196.
Surget A, Wang Y, Leman S, Ibarguen-Vargas Y, Edgar N, Griebel G et al (2009). Corticolimbic transcriptome changes are state-dependent and region-specific in a rodent model of depression and of antidepressant reversal. Neuropsychopharmacol, in press.
Simson PE, Weiss JM (1988). Altered activity of the locus coeruleus in an animal model of depression. Neuropsychopharmacol 1: 287–295.
Todorovic C, Sherrin T, Pitts M, Hippel C, Rayner M, Spiess J (2009). Suppression of the MEK/ERK signaling pathway reverses depression-like behaviors of CRF(2)-deficient mice. Neuropsychopharmacol, in press.
Zhou R, Yuan P, Wang Y, Hunsberger JG, Elkahloun A, Wei Y et al (2009). Evidence for selective microRNAs and their effectors as common long-term targets for the actions of mood stabilizers. Neuropsychopharmacol, in press.
Acknowledgements
We were supported in part by grants from the National Institutes of Health (MH063266 and DA012736 to WAC; DA023606 to EHC) while writing this commentary.
Author information
Authors and Affiliations
Corresponding author
Additional information
DISCLOSURE
We report no conflicts of interest related to this commentary. Dr Carlezon has a US patent and several US patent applications covering the use of novel approaches for treating depressive illness. He has received compensation from Infinity Pharmaceuticals, Myneurolab.com, and Psychogenics. Dr Chartoff has nothing to disclose.
Rights and permissions
About this article
Cite this article
Carlezon, W., Chartoff, E. Perspective: Progress on the Study and Treatment of Depressive Illness. Neuropsychopharmacol 34, 1361–1362 (2009). https://doi.org/10.1038/npp.2009.16
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/npp.2009.16